Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Ficho

Internal Medicine Glenview, IL Medical Doctor

NPI 1336141746 CMS profile 151240

2501 Compass Rd, Suite 110, Glenview, IL 60026

Open in the dashboard

General payments

$16,168

841 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Ficho of Glenview, IL is reported in the CMS Open Payments database as having received $16,168 across 841 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,433 63
2024 General $2,784 126
2023 General $2,281 114
2022 General $2,619 117
2021 General $2,425 136
2020 General $2,094 127
2019 General $2,532 158

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Ficho
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Thomas Ficho were reported at $1,433. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Thomas Ficho Internal Medicine median Middle half National median
2019 $2,532 $159 $48–$570 $163
2020 $2,094 $119 $33–$402 $114
2021 $2,425 $135 $37–$521 $132
2022 $2,619 $141 $42–$496 $149
2023 $2,281 $149 $45–$519 $160
2024 $2,784 $154 $47–$537 $164
2025 $1,433 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $2,555 140 payments
  2. AbbVie, Inc. $1,860 94 payments
  3. Pfizer Inc. $1,289 57 payments
  4. Lilly USA, LLC $1,260 65 payments
  5. Amgen Inc. $1,188 63 payments
  6. AstraZeneca Pharmaceuticals LP $946 51 payments
  7. Amneal Pharmaceuticals LLC $907 50 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $815 41 payments
  9. GlaxoSmithKline, LLC. $812 38 payments
  10. Janssen Pharmaceuticals, Inc $576 27 payments
  11. Other $3,959 215 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,154 839 payments
  2. Education $14 2 payments
Products named General payments · program years 2019–2025
  1. Ozempic $1,208 60 payments
  2. VRAYLAR $986 45 payments
  3. RYBELSUS $917 48 payments
  4. Repatha $917 49 payments
  5. UNITHROID $907 50 payments
  6. Otezla $643 38 payments
  7. JARDIANCE Diabetes $600 31 payments
  8. JARDIANCE Diabetes $544 29 payments
  9. ELIQUIS $539 23 payments
  10. XARELTO $521 25 payments
  11. Other $13,719 720 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 90 drugs

Part D claims

5,039

Median for Internal Medicine: 777

Drug cost

$578,832

Median for Internal Medicine: $73,373

Branded share of claims

24.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 76 $119,105
Mounjaro Tirzepatide Brand 79 $113,667
Eliquis Apixaban Brand 85 $86,601
Xarelto Rivaroxaban Brand 62 $56,855
Farxiga Dapagliflozin Propanediol Brand 30 $45,396
Repatha Sureclick Evolocumab Brand 19 $23,859
Jardiance Empagliflozin Brand 16 $19,528
Rosuvastatin Calcium Generic 946 $16,431
Trulicity Dulaglutide Brand 11 $11,863
Xigduo Xr Dapaglifloz Propaned/Metformin Brand 13 $10,545

The 10 drugs with the highest cost, of 90 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$302,190

Of which drugs: $93,231

Medicare patients

465

Average age 75

Services billed

5,141

177 women, 288 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 52%
Ischemic heart disease 50%
Arthritis 40%
Osteoporosis 20%
Diabetes 16%
Cancer 15%
Atrial fibrillation 12%
Chronic kidney disease 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 114 114 $32,948
Sarscv2 vac 30mcg trs-suc im 91320 Office 142 162 $23,535
Influenza vaccine, trivalent derived from recombinant dna 90673 Office 176 176 $14,400
Vaccine for influenza for injection into muscle 90662 Office 17 17 $1,223

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UNITHROID
$240 27 —
VRAYLAR
$226 — —
TRELEGY ELLIPTA
$203 — —
SHINGRIX
$201 — —
ZEPBOUND
$161 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

841 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record